Monopar Therapeutics Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Monopar Therapeutics Inc. (MNPR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $291.73 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-12
- Monopar Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Monopar Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2026-03-31 was $291.73K, a 2845.83% increase year-over-year.
- Monopar Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $164.09K.
- Monopar Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- Monopar Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $291.43K.
- Monopar Therapeutics Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $291.73K 10-Q · filed 2026-08-12 | $455.81K derived: sum of 3 quarters · filed 2026-08-12 | $455.81K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $291.73K 10-Q · filed 2026-05-14 | $455.81K derived: sum of 2 quarters · filed 2026-05-14 | $455.81K derived: sum of 3 quarters · filed 2026-05-14 | $573.25K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $164.09K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $164.09K derived: sum of 2 quarters · filed 2026-03-27 | $281.53K derived: sum of 3 quarters · filed 2026-08-12 | $291.43K 10-K · filed 2026-03-27 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $117.44K derived: sum of 2 quarters · filed 2026-08-12 | $127.34K 10-Q · filed 2025-11-13 | $127.34K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $117.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $127.34K 10-Q · filed 2026-08-12 | $127.34K derived: sum of 3 quarters · filed 2026-08-12 | $127.34K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $9.90K 10-Q · filed 2026-05-14 | $9.90K derived: sum of 2 quarters · filed 2026-05-14 | $9.90K derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $0.00 10-K · filed 2026-03-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |